Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA

European Heart Journal

Volumn 24, Issue 1, 2003, Pages 77-85

  Lenderink, T ^a   Boersma, E ^a   Heeschen, C ^b   Vahanian, A ^d   De Boer, M J ^e   Umans, V ^f   Van den Brand, M J B M ^a   Hamm, C W ^c   Simoons, M L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Kerckhoff Heart Center   (Germany)

^d HÔPITAL TENON   (France)

^e HOSPITAL DE WEEZENLANDEN   (Netherlands)

^f Location Alkmaar   (Netherlands)

Author keywords

C reactive protein; Glycoprotein IIb IIIa receptor antagonist; Long term follow up; Troponin T; Unstable angina pectoris

Indexed keywords

ABCIXIMAB; C REACTIVE PROTEIN; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; TROPONIN T;

ADULT; AGED; ANGIOCARDIOGRAPHY; CHEMOLUMINESCENCE; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHELOMETRY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CHRONIC DISEASE; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TROPONIN T;

EID: 0037234744     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00322-6     Document Type: Conference Paper

References (33)

1. Haverkate F, Thompson SG, Pyke SDM et al. For the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
2. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
3. Ridker PM, Rifai N, Stampfer MJ et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101: 1767-72.
4. Hamm CW, Ravkilde J, Gerhardt W et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992;327:146-50.
5. Hamm CW, Heeschen C, Goldmann B et al. For the CAPTURE study investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-9.
6. Heeschen C, Hamm CW, Goldmann B et al. For the PRISM investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757-62.
7. The CAPTURE Investigators. Randomised placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
8. Heeschen C, Hamm CW, Bruemmer J et al. for the CAPTURE Investigators. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol 2000;35:1535-42.
9. Ronner E, Dykun Y, Van den Brand MJBM et al. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Eur Heart J 1998;19:1608-16, doi: 10.1053/euhj.1998.1222.
10. Kong DF, Califf RM, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98:2829-35.
11. Topol EJ, Ferguson JJ, Weisman HF et al. For the EPIC Investigator Group. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-84.
12. Lindahl B, Toss H, Siegbahn A et al. For the FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engi J Med 2000;343:1139-47.
13. Lincoff AM, Tcheng JE, Califf RM et al. For the EPILOG investigators. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Circulation 1999;99:1951-8.
14. The EPISTENT investigators. Randomised placebo controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
15. Brener SJ, Barr LA, Burchenal JE et al. for the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angio plasty for acute myocardial infarction. Circulation 1998;98:734-41.
16. Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.
17. Anderson KM, Califf RM, Stone GW et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059-65.
18. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336;973-9.
19. Heeschen C, van den Brand MJ, Hamm CW et al. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999;100: 1509-14.
20. Liuzzo G, Biassuci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
21. Hingorani AD, Cross J, Kharbanda RK et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000;102:994-9.
22. Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
23. Zhang YX, Cliff WJ, Schoefl GI et al. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999;145:375-9.
24. Biasucci LM, Liuzzo G, Grillo RL et al. Elevated levels of C-reactive protein at discharge predict recurrent instability. Circulation 1999;99:855-60.
25. Tataru MC, Heinrich J, Junker R et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000; 21:1000-8, doi: 10.1053/euhi.1999.1981.
26. Buffon A, Liuzzo G, Biasucci LM et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
27. Lincoff AM, Kereiakes DJ, Mascelli MA et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-7.
28. Liuzzo G, Buffon A, Biasucci LM et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998;98:2370-6.
29. Leebeek FWG, Boersma E, Cannon CP et al. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease; why were the results so unfavorable. Eur Heart J 2002;23:444-57, doi: 10.1053/euhj.2001.2751.
30. Bertrand ME, Simoons ML, Fox KAA et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; Recommendations of the task force of the European society of cardiology. Eur Heart J 2000; 21:1406-32, doi: 10.1053/euhj.2000.2301.
31. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.
32. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002. Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf
33. Ronner E, Boersma E, Akkerhuis KM et al. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J 2002; 23:239-46, doi: 10.1053/euhj.2001.2736.